News - Iclusig

Filter

Current filters:

Iclusig

Popular Filters

EMA/CHMP recommends changes in use of Iclusig to minimize risk of blood clots

EMA/CHMP recommends changes in use of Iclusig to minimize risk of blood clots

23-11-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use has made a number of…

Ariad PharmaceuticalsEuropeIclusigOncologyPharmaceuticalRegulation

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

09-11-2013

At its November 4-7 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

acipimoxAnti-Arthritics/RheumaticsAriad PharmaceuticalsCardio-vasculardiacereinEuropeIclusigOncologyPharmaceuticalRegulation

Ariad Pharma “temporarily” suspends only marketed drug Iclusig in USA

Ariad Pharma “temporarily” suspends only marketed drug Iclusig in USA

01-11-2013

US drugmaker Ariad Pharmaceutical says it temporarily suspending the marketing and commercial distribution…

Ariad PharmaceuticalsIclusigMarkets & MarketingNorth AmericaOncologyPharmaceuticalRegulation

Ariad stops Ph III Iclusing trial on blood clot woes

18-10-2013

US biotech firm Ariad Pharmaceuticals’took another tumble, falling 35% to $2.91, as the company said…

Ariad PharmaceuticalsBiotechnologyIclusigNorth AmericaOncologyRegulationResearch

US FDA investigating stricken Ariad over Iclusig safety concerns

US FDA investigating stricken Ariad over Iclusig safety concerns

14-10-2013

The US FDA is investigating an increasing frequency of reports of serious and life-threatening blood…

Ariad PharmaceuticalsIclusigNorth AmericaOncologyPharmaceuticalRegulation

Long-awaited vaccine brings hope for millions

Long-awaited vaccine brings hope for millions

11-10-2013

Here's our take on the week's top stories.

AdempasEuropeGlaxoSmithKlineIclusigNorth America

FDA clinical hold on Iclusig sees Ariad stock go into free-fall

FDA clinical hold on Iclusig sees Ariad stock go into free-fall

10-10-2013

US drugmaker Ariad Pharmaceuticals saw its shares plunge 59% to $6.99 yesterday, wiping $2 billion off…

Ariad PharmaceuticalsBiotechnologyIclusigNorth AmericaOncologyRegulationResearch

Ariad's cancer drug Iclusig granted marketing authorization in the EU for leukemia

02-07-2013

USA-based Ariad Pharmaceuticals (Nasdaq: ARIA) yesterday (July 2) announced that it has been granted…

Ariad PharmaceuticalsIclusigMarkets & MarketingOncologyPharmaceutical

Back to top